Introduction
Chronic Fatigue Syndrome (CFS)/ Myalgic Encephalomyelitis (ME) and Fibromyalgia (FM) are disabling syndromes, without an established aetiology, a diagnostic test, or curative treatment. [1] [2] [3] Currently these complex syndromes are governed by their own individual diagnostic criteria and management direction, but display overwhelming evidence of similar symptoms. The prevalence of CFS/ME is estimated that in General Practice 10 patients in 10,000 (0.4%) are likely to have CFS/ME. 4, 5 The prevalence of FM has been recorded as 2-3% of the population. 5 Early research addressing the similarities of CFS/ME and FM dates back to the 1990's, most of which were preformed prior to the development and publishing of the accepted American Centre for Disease Control (CDC) Criteria 6 for diagnosis CFS/ME (Table 1) , and when the American College of Rheumatology (ACR) 7 diagnostic criterion for FM was in its infancy. These may be obsolescent, but are relevant in the context of the current research. Much of the literature available may discuss CFS/ME and FM together, however little research actually investigates if the symptom experience is the same. 1,4, 8- gastrointestinal symptoms; pain; fatigue; sleep disturbance; anxiety and/or depression; impact on self esteem and reduced Quality of Life. 8, 14 Evidence suggests that pain is one of the prominent symptoms associated with both syndromes, although historically this has been one of the dividing factors during diagnosis, when the similarities between these syndromes outweigh the differences. 7, 8, 11, 15, 16 Confirming a diagnosis of CFS/ME or FM is a long and complex processes due to the subtle differences in the initial presenting symptoms. 8, 11, 14 Evaluating the evidence presented in context with medical advances and increasing investment in research, suggested a need to revisit this area of study. Considering these issues and to provide the most appropriate evidence based care, it is important to investigate these syndromes, as similar management strategies may be beneficial for both groups.
US Case Definition of Chronic Fatigue Syndrome (Fukuda et al, 1994)
1. medically unexplained chronic fatigue, of new onset > 6 months, which is 2. not substantially alleviated by rest, not the result of ongoing exertion, 3 . substantial reduction in occupational, educational, social and personal activities.
Anxiety and depression are not always excluded
The following conditions, if present, exclude diagnosis of CFS: past or current major depression with melancholic or psychotic features, delusional disorders, bipolar disorders, schizophrenia, anorexia nervosa, bulimia, or alcoholic or substance abuse within 2 years before the onset of CFS or any time afterward.
2. > 4 or more symptoms, occur for > 6 months These are Self reported persistent or recurrent impairment in short-term memory or concentration severe enough to cause substantial reductions in previous levels of occupational, educational, social, or personal activities a) Sore throat The purpose of this, the first phase was primarily to confirm the symptoms and their severity in CFS/ME and FM and to identify any occurring themes. At present in the absence of evidence confirming CFS/ME and FM share the same underlying pathology, it may be reasonable to suggest they have strong overlapping symptoms, which should be afforded all the same management options. The evidence presented will create the foundation of the second phase, to establish if a relationship exists between the symptoms of CFS/ME and FM.
Methods

Participants
People self selected to participate and were recruited through advertisements on the internet and through CFS/ME and FM self help groups. Participants were aged > 16 with a confirmed diagnosis of CFS/ME or FM from a General Practitioner (GP) or specialist were included. Participants with CFS/ME were required to satisfy the requirements of the American (CDC) Criteria for CFS/ME 6 and participants with FM were required to satisfy the ACR Criteria. 7 Suitability for inclusion was based on screening answers to questions. Exclusions were as a result of any additional chronic conditions or anxiety and depression, self diagnosis, or incomplete data sets.
Consent
A web-based template (www.cfsfibromy.co.uk) was designed to capture data using a number of questionnaires. Informed consent was confirmed electronically, and may have been retracted up to the point of data analysis. Ethical approval for this study was granted by the appropriate University.
Data Collection
Nine questionnaires had formerly been subject to validity and reliability checks and reflect the main symptoms and issues which impact people with CFS/ME and FM (Table   1 ). These sections comprised the disease specific questionnaire for CFS/ME, the American CDC Symptom Inventory and diagnostic criterion for CFS/ME, 6, 17 and for FM the ACR diagnostic criterion for FM 7 and the Fibromyalgia Impact Questionnaire (FIQ). 18, 19, 20 The remaining questionnaires measured symptoms identified, as follows: 26 and The Rosenberg
Self-Esteem Scale (RSES). 27 Each questionnaire had its own discrete set of instructions, with a consent section at the beginning, detailed in Table 2 .
In addition, questions were posed to collect demographic and comprehensive information on the sample. Details of the research were presented to facilitate the participants submitting their consent. Data were manually screened to confirm all questionnaires were fully completed and submitted, prior to analysis. 
Results
Descriptive statistics were used to report demographic details. Individual scoring methods for each of the questionnaires confirmed participant's symptom experience, if they satisfied the requirements of the American CDC Criteria for CFS/ME 6 CFS/ME 45.5%, (n = 46) participants were more readily diagnosed by a General Practitioner. In the case of FM a greater portion were diagnosed by a Rheumatologist 57.9% (n = 62).
All participants with CFS/ME confirmed that they had experienced their symptoms for the required > 6 months, and > 3 months for a FM diagnosis. 7, 15 The CFS/ME group experienced their symptoms for a M = 10.69 years SD = 8.91, ranging from 1 year to 37 years. Participants with FM experienced symptoms for ranging from 1 year to 28 years, M = 12.62 years SD = 9.85.
All participants experienced more than the minimum requirement of > 5 symptoms listed by the American CDC criteria, 7.9% CFS/ME (n = 8) and FM 1.8% (n = 2) groups. With both groups experiencing > 4 symptoms required confirming the requirements of the CFS/ME criteria. 6 17 The maximum number of 8 additional symptoms was experienced by the CFS/ME 49.0% (n = 51) and FM 59.8% (n = 61) groups.
The CFS/ME group (n = 101) had a Median score of 8 and Mode of 6 pain points, below the minimum requirement of 11. The FM (n = 107) group presented with a Median of 14 and Mode of 18 pain points, based on the ACR diagnostic criteria for FM, 7 exceeding the minimum required number of 11 pain points. The most frequent number of pain points reported by the CFS/ME group were 6 (n = 14), followed by 10 and then 8 pain points (n = 12). In the FM group the most frequently reported number of pain points were 18 (n = 31 participants) followed by 16 and 14 (n = 14 participants). The total number of participants with > 11 pain points for CFS/ME was 29.7% (n = 30) and FM was 76.6% (n = 82). Figures 1 and 2 illustrate the areas of the body based on the MPQ which incorporate the ACR criteria for FM pain points, where participants indicated they experienced their pain.
(Insert Figure 1) The total numbers of pain points were calculated by assessing the areas where participants indicated their pain was located. The main areas identified by both groups were the cervical areas 52.5% (n = 53), CFS/ME and for FM 64.5% (n = 69) and the upper shoulders 52.5% (n = 53), for CFS/ME and 72% (n = 77), for FM ( Fig.1 ). In addition, 66.4% (n = 71) of FM participants experienced pain in their lower backs. This was also the second most problematic area of pain recorded for the CFS/ME group 31.7% (n = 32) to 45.5% (n = 46) all these areas included the ACR pain points (Fig.1) . A higher portion of the FM group reported pain in these areas when compared to the CFS/ME group.
(Insert Figure 2) The main areas of pain identified for the anterior view of the body (Fig. 2) were the neck for 36.6% (n = 37) for the CFS/ME group, and 54.2% (n = 58) of the FM group, but in this instance no pain points were included. The chest area, which includes the pain points, were found to be problematic for both groups with 43.0% (n = 46) of the FM participants and 23.3% of the CFS/ME participants selecting this area. In addition participants were able to indicate areas of the body they experienced pain which did not incorporate the ACR pain points, concluding that pain was experienced in multiple areas of the body including the face and head which are not indicative of the ACR pain points for diagnosis. Table 3 presents the results for the participants Mean scores for the individual questionnaires for both groups. Scores ranged between 4 and 20, with total scores not recommended. The minimum score identified for the CFS/ME group was 4 for physical fatigue and reduced motivation, and the maximum score was 20, for the remaining items of the MFI, the minimum scores were identified as > 5 with the maximum score of 20. In the CFS/ME sample, 99.0% of (n = 100) participants experienced fatigue on each domain of the MFI. In the FM group the minimum score for general fatigue and physical fatigue was 4 with the minimum score on the remaining domains > 5, and the maximum score on all the domains were 20. In the FM sample 98.1% of (n = 105) participants experienced fatigue on all the domains of the MFI. These results confirmed that both the CFS/ME and FM groups experienced a high level of fatigue, a symptom which is indicative of a diagnosis of CFS/ME and associated with FM.
PSQI
The PSQI 29 confirmed poor sleep quality in 43.6% (n = 44) of CFS/ME and 47.7%
(n = 51) of FM participants. The number of participants who had taken Medication > 3 times per month to assist with sleep were 39.6% (n = 40) of the CFS/ME group, and 41.1% (n = 44) of the FM group. The minimum total score recorded for poor sleep quality on the PSQI for the CFS/ME group was 5, and the maximum was 20. The minimum total score on the PSQI for the FM group was 3 and the maximum score was 21. These findings confirm that both the CFS/ME and FM groups experienced poor sleep quality.
SF-36 V2
The SF-36 V2 25 confirmed reduced HRQoL in both groups. Scores closer to 0 suggest impaired, and scores closer to 100 suggest the best HRQoL. 31 The results presented in Table 3 confirm participants with CFS/ME and FM have a reduced HRQoL with the Mean scores on most of the components below 50. The exceptions were for the mental health and role mental functioning components, where scores were > 50 which suggests participants HRQoL was not affected by their mental health. Role physical function was found to have the greatest impact on both the CFS/ME and FM groups. Role mental function did not have as big an impact on participants HRQoL.
HADS
The results for the total score for anxiety on the HADS 24 ranged from 0 to 20 and confirmed that out of the total sample of CFS/ME (n = 101) 49.5% (n = 50), and FM (n = 107) 27.1% (n = 29) participants, did not display symptoms of anxiety. 32 There was a borderline case of anxiety for 14.9% (n = 15) of CFS/ME and 20.5% (n = 22) of FM participants, with the remaining 35.6% (n = 36) of CFS/ME and 52.3% (n = 56) of FM participants confirmed as displaying symptoms of anxiety.
The total score for depression identified that 37.6% (n = 38) of CFS/ME and 28.0%
(n = 30) of FM participants did not display symptoms of depression. There was a borderline case for depression for 32.6% (n = 33) of CFS/ME and 30.8% (n = 33) of FM participants. The remaining 29.7% (n = 30) of CFS/ME and 41.1% (n = 44) of FM participants in this sample expressed symptoms of depression.
The total score on the HADS confirmed that 9.9% (n = 10) of CFS/ME and 2.8% (n = 3)
of FM participants did not display symptoms of anxiety and depression. There was a possible caseness for 15.8% (n = 16) of the CFS/ME and 4.8% (n = 5) of FM participants for anxiety and depression. The remaining 74.0 (n = 75) of CFS/ME and 92.5% (n = 99) of FM participants confirmed they were affected by symptoms of anxiety and depression.
These results confirmed that both groups experience some degree of anxiety and depression, with the FM group displaying higher scores on the HADS than the CFS/ME group.
MHLOC
A total score is not recommended for the MHLOC, 26 the scores for the internal and chance scales range between 6 and 36. 33 The scores for the doctors and powerful other scales range between 3 and 18. Higher scores on a particular scale suggest stronger beliefs in that area, either internal or external locus of control. The Mean score for the internal and chance scores for CFS/ ME are just on the Median (n = 18), for these subscales and below the Median score (n = 9) for the external scores (doctors and other people). Results for the FM group identify slightly higher scores than the Median score for the internal sum and below the Median scores for chance, doctors and other people.
The minimum score for both groups on the internal and chance scales were 6 where the maximum score was 33, for the CFS/ME group and 35 for the FM group on the internal scale. The maximum result on the chance scale for the CFS/ME group were 33 and for the FM group 32. The minimum score calculated for the doctors and other people scales were 3 for both groups. The maximum score recorded for the CFS/ME group on the doctors domain was 17, and for the FM group was recorded as 18. The maximum score recorded for other people for both groups was 18. The results presented suggest on average the CFS/ME and FM groups present with similar scores.
RSES
The RSES 34 scores range from 0 to 30. Results did not confirm that either the CFS/ME or FM groups presented with scores > 25. In the CFS/ME group 36.6% (n = 37) and in the FM group 53.3% (n = 57) of participants confirmed scores < 15. These results suggest that the FM group experienced a lower degree of self esteem than the CFS/ME group.
Discussion
Unlike historical research into CFS/ME and FM this research measured the symptoms of CFS/ME and FM using self assessment questionnaires to confirm and reaffirm the nature of symptoms associated with CFS/ME and FM. The characteristics, such as age and gender of the CFS/ME and FM groups are supported by historical findings of CFS/ME and FM. 5 35 Both groups confirmed their diagnosis by satisfying the requirements of the CFS/ME criteria 6 and the FM criteria. 7 The specialty of Clinicians who diagnosed the participants in this sample of CFS/ME and FM is also characteristic of earlier findings. Diagnosis of CFS/ME by a GP are not unexpected where in contrast people with FM are more readily assessed and receive their diagnosis from a Rheumatologist or a General Practitioner. 36 In contrast people with CFS/ME are not readily assessed or referred onto specialist services, as supported by the current findings. 3 This suggests that people with FM more readily have access to specialist services than patients with CFS/ME.
The results from the CFS/ME group confirmed that not all participants satisfied the minimum of 11 pain points to comply with the requirements of the FM criteria. However, the MPQ presents clear evidence that the CFS/ME group experienced pain in different areas of the body, confirming pain is as debilitating a symptom as in FM. This is revealing as the reviewed FM criteria 2 has removed the highly prescriptive pain points, and focuses on areas of pain, to assess the patient holistically. Furthermore there is evidence which highlights that the complex nature of this pain assessment has led to it being performed incorrectly or omitted by Clinicians as a diagnostic tool for FM. 37 Taking all these factors into consideration it may be reasonable to concluded in this instance that this sample of participants satisfied the requirements of the FM criteria. 8 In contrast the FM group confirmed they met the requirements of the CFS/ME criteria.
Pain is widely documented as a defining feature for a diagnosis of FM 2,7 and fatigue has been the primary symptom associated with a diagnosis of CFS/ME. 18, 38 Taking this into consideration with the results presented from the MPQ, PSQI and MFI confirmed that both groups experienced pain and fatigue which impacted on their HRQoL. The high levels of pain identified reflect the findings from studies comparing CFS/ME and FM with other painful conditions such as chronic pain and arthritis, which identified their pain was equivocal. 39, 40 The findings presented from the MFI confirms that the debilitating fatigue that plagues people in CFS/ME is also an issue for people with FM. This suggests that the symptom of fatigue in FM is as much a management priority as pain, as it is a distressing symptom identified as negatively impacting on a patient's quality of life 23 In view of these findings and current research, this suggests that the individual diagnostic criteria for CFS/ME and FM are sensitive towards the diagnosis they are designed for. Therefore consideration should be given to reviewing current published guidelines for CFS/ME in view of the arguments provided for not creating guidelines for
FM. 17
In addition to pain and fatigue our findings confirmed that both groups experienced poor sleep quality, and reduced HRQoL with the list of symptoms being extensive.
Furthermore participants in both groups experienced these symptoms to a debilitating degree, which caused impairment and had an impact on their daily lives. These groups did not confirm high levels of anxiety, depression or low self esteem, which are in contrast to historical reports, suggesting this is not the main pressing issues in CFS/ME and FM. 34, 35, 3, 41 With the current lack of successful management plans and taking these findings into consideration, improvement to HRQoL should be given priority in patients with CFS/ME and FM. This is pertinent as it has been identified that CFS/ME and FM negatively impact on occupational, social, personal and economical aspects, which are frustrating and devastating for a person who previously enjoyed good health. 42, 43 These results raise questions regarding compartmentalizing the symptoms into either a diagnosis of CFS/ME or FM. Fatigue, the main symptom used to make a diagnosis of CFS/ME and Pain, the primary diagnostic symptom of FM, have both been confirmed as problematic for both groups. These findings suggest that there is a grey area between the two diagnoses. The data presented suggests that the similarities between the symptoms measured outweigh any differences. The evidence presented provides compelling debate to recommend that further research in this area is undertaken. This would further investigate the significance of the current findings, to identify if there maybe ramifications for the classification of CFS/ME and FM and its future management.
Strengths and Limitations of this study
To our knowledge this is the first study to assess the symptom experience of CFS/ME and FM using the methods described. This study brings attention to an area with CFS/ME and FM which has not been researched in a number of years.
Conclusion
This preliminary data provided evidence of a high level of symptoms which impact on daily life. Furthermore the results suggest that both groups experience a high level of pain which is not always localised to the prescriptive pain areas outlined by the ACR criteria for FM. In addition both groups experience debilitating fatigue. The strong evidence presented in this first part of the study, alludes to the fact that both CFS/ME and FM may have a similar symptoms experience, and this should be afforded more investigation.
What is already known on this topic Both groups share similar symptoms but it has not been confirmed whether they are the same syndrome. Historically pain is the main diagnostic factor in FM and fatigue is the main diagnostic factor in CFS/ME. Separate diagnostic criteria exist for CFS/ME and FM but their trajectory of management options may be different based on diagnosis.
Research into this area is obsolescent.
What this research adds
To date this approach to assessing the symptom experience of CFS/ME and FM has not been used. This study confirms that fatigue associated with CFS/ME and pain associated with FM maybe problematic for each group regardless of diagnosis. Pain and Fatigue were historically key defining symptoms. This study highlights that in the absence of specific aetiology confirming the cause of CFS/ME and FM there is a need to address HRQoL where management options are limited or unsuccessful. This research provides a basis for future research to establish if the syndrome experience of CFS/ME and FM are the same.
